Maravai LifeSciences Holdings Inc Ordinary Shares - Class A (MRVI)

Industry Biotechnology
This stock can be held in an Investment ISA and an Investment Account
Sell

$2.25

Buy

$2.44

arrow-down$-0.12 (-5.06%)

Prices updated at 30 May 2025, 21:36 EDT
| Prices minimum 15 mins delay
|
Prices in USD
NASDAQ
arrow-down-0.32%
NASDAQ
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
Our Investment Fees and Charges.
Sector
Healthcare
Industry
Biotechnology
Chairman
Mr. Robert Andrew Eckert
CEO
Mr. William E. Martin, III
Most recent earnings
31 Dec 2024
Fiscal year end
31 Dec 2024
Employees
580
Head office
10770 Wateridge Circle
San Diego
United States
92121
mobile
+1 858 546-0004
letter
david.weber@maravai.com
computer
Company website

Key personnel

Owner nameSalaryBonusAll other compensationTotal compensationRestricted stock award
Mr. Gregory T. Lucier
Independent Director
0.06m--0.28m-
Dr. John A. DeFord, PhD
Independent Director
0.09m--0.31m-
Dr. Peter M. Leddy, PhD
Chief Administrative Officer
0.48m0.07m-2.36m-
Dr. Jessica Hopfield, PhD
Independent Director
0.09m--0.31m-
Mr. Kevin Herde
Chief Financial Officer and Principal Accounting Officer
0.49m0.07m-2.34m-
Ms. Christine Dolan
Executive Vice President and General Manager, Cygnus Technologies
-----
Mr. Sean L. Cunningham
Director
0.07m--0.29m-
Mr. Constantine S. Mihas
Director
0.07m--0.29m-
Mr. Kurt Oreshack
General Counsel and Secretary
-----
Mr. Benjamin Daverman
Director
0.06m--0.28m-
Ms. Susannah Gray, M.B.A.
Independent Director
0.10m--0.32m-
Mr. Luke Marker
Director
0.06m--0.28m-
Dr. Murali K. Prahalad, PhD
Independent Director
0.07m--0.29m-
Mr. William E. Martin, III
Chief Executive Officer and Director
0.78m--6.38m-
Ms. Rebecca Buzzeo
Executive Vice President and Chief Commercial Officer
0.47m0.05m-2.46m-
Mr. Robert Andrew Eckert
Chairman of the Board
---0.22m-

Top 5 shareholders

Owner nameNo. of sharesShare as % of port.Last changePortfolio % changeDate of portfolio% Total assets
GTCR Investment XI LLC130,834,085--9940974-7.06160230 Apr 202592.24
GTCR LLC20,150,0054.99248--30 Apr 202514.00
12 West Capital Management LP12,521,3354.083999300008.02323530 Apr 20258.70
Vanguard Group Inc11,658,9410.00047-162483-1.37447930 Apr 20258.10
BlackRock Inc9,548,8330.00044-229091-2.34294130 Apr 20256.63

Director dealings

DateActionNamePriceValueNo. of sharesHolding (%)Additional info
09 Dec 2024-Mr. Gregory T. Lucier--20,645--
09 Dec 2024-Mr. Gregory T. Lucier--55,123--
15 Nov 2024-Ms. Rebecca Buzzeo4.4219,284360,703--
12 Nov 2024-Dr. John A. DeFord, PhD5.75100,62570,046--
11 Nov 2024-Mr. Carl W. Hull5.64987,000175,000--
31 Oct 2024-Mr. Kevin Herde5.7010,864336,600--
31 Oct 2024-Ms. Christine Dolan5.7010,534260,338--
31 Oct 2024-Mr. Kurt Oreshack5.702,086224,056--
31 Oct 2024-Mr. Andrew Burch5.7010,494423,595--
15 Oct 2024-Mr. William Martin, III8.29421,488989,430--
15 Jul 2024-Dr. Peter M. Leddy, PhD8.7645,149375,781--
23 May 2024-Mr. Gregory T. Lucier10.78222,55375,768--
23 May 2024-Dr. John A. DeFord, PhD10.78222,55352,546--
23 May 2024-Dr. Jessica Hopfield, PhD10.78222,553110,768--
23 May 2024-Mr. Sean L. Cunningham10.78222,55348,916--
23 May 2024-Mr. Constantine S. Mihas10.78222,55348,916--
23 May 2024-Mr. Benjamin Daverman10.78222,55348,916--
23 May 2024-Ms. Susannah Gray, M.B.A.10.78222,55380,768--
23 May 2024-Mr. Luke Marker10.78222,55348,916--
23 May 2024-Dr. Murali K. Prahalad, PhD10.78222,55365,468--
Please note that past performance is not a reliable indicator of future returns.


Important Information

Please note the value of investments can go down as well as up so you may get back less than you invested. This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to an authorised financial adviser. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and(3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
© Copyright 2025 Morningstar. All rights reserved.